BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Therapeutic Court Association of Washington and Washington Association of Drug Courts - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://tcaofwa.org
X-WR-CALDESC:Events for Therapeutic Court Association of Washington and Washington Association of Drug Courts
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260506T100000
DTEND;TZID=America/Los_Angeles:20260506T113000
DTSTAMP:20260511T061227
CREATED:20260327T192446Z
LAST-MODIFIED:20260327T192446Z
UID:9320-1778061600-1778067000@tcaofwa.org
SUMMARY:Integrated Employment Institute: Work Incentives and Social Security
DESCRIPTION:Washington Health Care Authority (HCA) Foundational Community Supports (FCS) team in partnership with Rutgers School of Psychiatric Rehabilitation and Counseling Professions are hosting a Supported Employment series. \nOften\, job seekers are unsure about returning to work because they are concerned about how work affects Social Security. This two-part training provides an overview of the types of work incentives available to SSI and SSDI recipients. Part one will review specific work-related information relevant to Supplemental Security Income (SSI)\, and part two will cover Social Security Disability Insurance (SSDI). \nWebinar information\nPart 1-\nDate: April 29\nTime: 10 am – 11:30 am \n\n\n\n\n\n\n\nRegister for part 1\n\n\n\n\n\n\n\nPart 2-\nDate: May 6\nTime: 10 am – 11:30 am \n\n\n\n\n\n\n\nRegister for part 2\n\n\n\n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/integrated-employment-institute-work-incentives-and-social-security-2/
LOCATION:Online
CATEGORIES:Accessibility,Advocacy,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2025/10/Washington-HCA.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260506T100000
DTEND;TZID=America/Los_Angeles:20260506T113000
DTSTAMP:20260511T061227
CREATED:20260430T171505Z
LAST-MODIFIED:20260430T171505Z
UID:9707-1778061600-1778067000@tcaofwa.org
SUMMARY:Best Practices in Trauma-Informed Care for Unhoused Populations
DESCRIPTION:Details \nPeople experiencing homelessness often face significant trauma\, including violence\, loss\, instability\, poverty\, and systemic barriers that can deeply impact trust\, behavior\, and engagement with services. This webinar will provide participants with a practical understanding of trauma-informed care and why it is essential when working with unhoused individuals and families.\nParticipants will explore how trauma can shape responses to stress\, relationships\, and service systems\, while learning strategies to create safer\, more respectful\, and person-centered interactions. The session will focus on approaches that reduce traumatization\, build trust\, and improve connections to housing\, behavioral health care\, and community support.\nDesigned for outreach teams\, shelter staff\, behavioral health providers\, case managers\, healthcare professionals\, and community partners\, this webinar offers actionable tools to strengthen engagement and improve outcomes for people experiencing homelessness. \nObjectives/Takeaways (at least three please)\n  Understand the Impact of Trauma\nRecognize how trauma\, chronic stress\, and adverse life experiences can affect behavior\, decision-making\, trust\, and engagement among people experiencing homelessness.\nApply Trauma-Informed Practices\nUse practical strategies that promote safety\, dignity\, choice\, empowerment\, and culturally responsive support when interacting with unhoused individuals.\nImprove Service Engagement and Outcomes\nIdentify ways to reduce traumatization\, strengthen relationships\, and increase successful connections to housing\, behavioral health\, and supportive services. \n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/best-practices-in-trauma-informed-care-for-unhoused-populations/
LOCATION:Online
CATEGORIES:Advocacy,Behavioral Health,Community Supervision,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2025/10/Washington-HCA.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260506T140000
DTEND;TZID=America/Los_Angeles:20260506T150000
DTSTAMP:20260511T061227
CREATED:20260327T005426Z
LAST-MODIFIED:20260327T005426Z
UID:9266-1778076000-1778079600@tcaofwa.org
SUMMARY:Update on the Diversification of Kratom-Derived Products: 7-Hydroxymitragynine\, Pseudoindoxyl and Beyond
DESCRIPTION:ORN Partner Organization Sponsor: American Osteopathic Academy of Addiction Medicine (AOAAM) \nWednesday May 6\, 2026 5:00 – 6:00 PM ET \nThis session will provide a background on traditional kratom and an overview of the recent proliferation of novel\, kratom-derived products. Industry marketing and media coverage will be described as all influence public health responses. Next steps for developing a better epidemiological understanding will be identified along with the roles clinicians play. The pharmacology of kratom\, 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl will be explained in a manner geared at helping clinicians understand how pharmacology influences addiction potential. Patient-level factors that may influence substance use disorder or adverse event trajectories will be articulated. Use motivations will be discussed alongside risks. \n\nORN Spring 2026: Update on the diversification of kratom-derived products: 7-hydroxymitragynine\, pseudoindoxyl\, and beyond \n\n\n\n\n\n\n\n\nDescription:\n\nThis talk will provide a background on traditional kratom and an overview of the recent proliferation of novel\, kratom-derived products. Industry marketing\, confused media coverage\, and dynamic government policy will be described\, as all influence public health responses. What is known about the harm-reduction aspects of these kratom compounds will be considered. Next steps for developing a better epidemiological understanding will be identified along with the roles clinicians play. The pharmacology of kratom\, 7-hydroxymitragynine (7-OH)\, and mitragynine pseudoindoxyl will be explained in a manner geared at helping clinicians understand how pharmacology influences addiction potential. Patient-level factors that may influence substance use disorder or adverse event trajectories will be articulated. Use motivations will be discussed alongside risks. Case reports will be used to highlight the complexity of assessing\, diagnosing\, and treating patients consuming new kratom-derived products. Ample time for attendee Q&A will be reserved to facilitate learning and discussion. \n\nLearning objectives:\nUpon completion\, participants will be able to: \n1. Upon completion\, describe the basic pharmacology\, toxicology\, effects\, risks\, and benefits associated with kratom and kratom-derived products containing 7-hydroxymitragynine (“7-OH”)\, mitragynine pseudoindoxyl (“pseudo”)\, along with related compounds such as kava\, and MGM-15.\n2. Upon completion\, participants will be able to engage in improved identification of kratom product use\, conduct highly specified clinical assessments\, and better diagnosis and manage SUDs related to kratom-derived products in a data-informed and patient-centered manner.\n3. Upon completion\, participants will be able to define the dynamic state and federal policy and regulatory landscape surrounding kratom and kratom-derived products. \n\nWhat is ORN\n\n\nHelp is here! The Opioid Response Network (ORN) is your resource for no-cost education\, training and consultation to enhance efforts addressing opioid and stimulant use disorders.\nORN has consultants in every state and territory to deploy across prevention\, treatment\, recovery and harm reduction.\nShare your needs via the “Submit a Request” form at www.OpioidResponseNetwork.org. Within one business day\, your regional point person will be in touch to learn more.\n\n\nSpeaker:\n\nDr. Kirsten Smith \n\nKirsten Smith\, Ph.D.\, L.M.S.W.\, is one of the nation’s leading clinical experts on kratom. Dr. Smith has authored over 90 peer-reviewed publications\, most focused on kratom or related topics\, including kava and tianeptine. Between 2023-2025\, Dr. Smith was an Assistant Professor in the Department of Psychiatry and Behavioral Sciences in the Johns Hopkins University School of Medicine. She joined Johns Hopkins after earning her Masters in Social Work from the University of Kentucky\, Ph.D. from the University of Louisville\, and after completing a 4-year postdoctoral fellowship at the National Institute on Drug Abuse Intramural Research Program (NIDA IRP). At NIDA IRP Dr. Smith completed her K99-funded project that involved a national ecological momentary assessment of kratom use and a controlled drug administration substudy that investigated the acute effects of commercial kratom products. Her NIDA R00-funded study at Johns Hopkins examined the pharmacokinetics/pharmacodynamics of kratom and assessed spontaneous kratom withdrawal among daily consumers. Dr. Smith was awarded a NIDA R01 to investigate the safety\, tolerability\, and human abuse potential of kratom extract in healthy adults\, which is ongoing. She has also conducted numerous surveys and qualitative data projects on kratom and 7-hydroxymitragynine use. Presently\, Dr. Smith is transitioning from academia to clinical practice but consults on kratom regularly and welcomes opportunities for collaboration. \n\n\nDISCLAIMER\nACCREDITATION:\nIn support of improving patient care\, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nDISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:\nAll conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships\, or the lack thereof\, will be provided to learners.\n\nFunding:\nFunding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names\, commercial practices\, or organizations imply endorsement by the U.S. Government.\n\n\n\n\nRegister Here: ORN Spring 2026: Update on the diversification of kratom-derived products: 7-hydroxymitragynine\, pseudoindoxyl\, and beyond\n\n\n“Therapeutic Court Association of Washington is sharing this event for informational purposes only and is not affiliated with\, endorsing\, or sponsoring the event.”
URL:https://tcaofwa.org/event/update-on-the-diversification-of-kratom-derived-products-7-hydroxymitragynine-pseudoindoxyl-and-beyond/
LOCATION:Online
CATEGORIES:Advocacy,SUD,Treatment,Webinar
ATTACH;FMTTYPE=image/png:https://tcaofwa.org/wp-content/uploads/2026/03/Screenshot-2026-03-26-175327.png
END:VEVENT
END:VCALENDAR